Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPain ManagementAetna Cryoanalgesia Coverage Update | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0297

    Cryoanalgesia and Therapeutic Cold

    Customize your policy alerts

    Sign up for Aetna Policy 0297 alerts

    Get alerted when Policy 0297 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs the medical necessity and coverage stance for cryoanalgesia and therapeutic cold devices and procedures, specifying covered indications (e.g., trigeminal neuralgia, perioperative cryoanalgesia for Nuss/Ravitch, and certain passive cold compression DME) and investigational or not covered uses.

    Policy Summary
    PayerAetna
    PolicyCryoanalgesia and Therapeutic Cold
    Policy CodePolicy 0297
    Change TypeNo material change
    Effective DateOct 13, 1998
    Last ReviewMar 16, 2023
    Next Review DateMar 14, 2024
    Key ActionEnsure patients have tried and failed or are intolerant of pharmacologic therapy for trigeminal neuralgia before considering cryoanalgesia.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Medically necessary indications
    10Experimental/investigational examples
    MultipleCode groups provided
    6 moTN repeat interval
    03/16/2023Last review

    Coverage Determinations and Evidence Summary

    Coverage and Experimental/Investigational

    Aetna considers the following medically necessary or experimental/investigational:

    Medically Necessary: The use of cryoanalgesia for the temporary relief of pain due to chronic refractory trigeminal neuralgia (selection criteria in Appendix). Pre-operative, intra-operative, and post-operative cryoanalgesia for post-operative pain management related to the Nuss or Ravitch procedure. Passive cold compression therapy units (e.g., Aircast Cryo/Cuff, Polar Care Cub, Polar Care Packs) and passive hot and cold therapy as medically necessary DME to control swelling, edema, hematoma, hemarthrosis and pain. Note: Mechanical circulating units with pumps have not been proven to be more effective than passive hot and cold therapy.

    See Appendix for TN selection criteria.

    Experimental/Investigational: Active cold units with mechanical pumps and portable refrigerators with or without compression therapy (e.g., AutoChill, BioCryo, Breg Polar Care Cube, Game Ready, Donjoy IceMan, Ossur Cold Rush, Hilotherm, VPULSE) are considered experimental/investigational. Cryoneurolysis for abdominal pain associated with pancreatic cancer, acute pain, cervicogenic headache, chronic head pain secondary to occipital neuralgia, peripheral neuropathic pain, phantom limb pain, and post-herpetic neuralgia; devices delivering both hot and cold therapy; intra-operative and post-operative cryoanalgesia for post-thoracotomy pain and for reduction of post-tonsillectomy pain; passive cold compression units for indications other than those listed as medically necessary; pre-operative cryoneurolysis for pain management following total knee arthroplasty; prophylactic hypothermia for traumatic brain injury; therapeutic hypothermia for hemorrhagic stroke; therapeutic induction of intra-brain hypothermia (e.g., pro2cool); and ultrasound-guided percutaneous intercostal cryoanalgesia for analgesia following mastectomy are considered experimental/investigational because effectiveness has not been established.
    Policy Summary
    PayerAetna
    PolicyCryoanalgesia and Therapeutic Cold
    Policy CodePolicy 0297
    Change TypeNo material change
    Effective DateOct 13, 1998
    Last ReviewMar 16, 2023
    Next Review DateMar 14, 2024
    Key ActionEnsure patients have tried and failed or are intolerant of pharmacologic therapy for trigeminal neuralgia before considering cryoanalgesia.
    SourceLink
    On This Page
    Coverage Determinations and Evidence SummaryCPT, HCPCS, and ICD-10 CodesAuthorization, Documentation, and Provider RequirementsClinical Background and DefinitionsPrior Treatments and Diagnostic RequirementsTreatment Frequency and Repeat IntervalsImaging and Procedural GuidanceServices and Devices Not Covered

    Lists examples and device models.

    Cryoanalgesia for pectus excavatum (Nuss/MIRPE)

    Evidence and outcomes reported in the literature (informational):

    Nuss/pectus repair evidence: Multiple observational studies and randomized trial(s) report that intra-operative intercostal nerve cryoablation during Nuss or minimally invasive pectus repair is associated with decreased length of stay, decreased inpatient opioid consumption, and equivalent pain control compared with thoracic epidural analgesia or PCA; operative time may be increased.

    Level of Evidence includes I-II-III across studies

    Intra-operative cryoanalgesia for tonsillectomy

    Systematic review findings:

    Tonsillectomy cryoanalgesia: A systematic review of limited-quality randomized controlled trials (3 trials, 153 participants) reported 21–31% less average post-operative pain with cryoanalgesia versus controls, with no differences in bleeding or time to resume diet; findings are preliminary and require validation by well-designed studies.

    Trials used cryotherapy probe or ice-water cooling

    Cold therapy units and hot/ice machines

    Cold therapy device evidence summary:

    Active vs passive cold therapy devices: Active (mechanical pump/refrigerated) and passive cold therapy devices are described in the literature; available studies are of limited quality and have not demonstrated consistent additional benefit of complex active devices over passive devices such as the Cryo/Cuff or conventional ice packs for post-operative outcomes. Aetna's policy is aligned with Medicare DME MAC regarding mechanical cold therapy pumps.

    Document cites lack of evidence for superiority of complex active units

    Evidence-based indications and limitations

    Evidence-summary based stance for specific indications

    Tonsillectomy cryoanalgesia: Small randomized trials suggest reduced post-operative pain versus controls but quality is limited and results are preliminary.

    See systematic review Raggio et al (2018).

    Prophylactic hypothermia for severe TBI: A large randomized trial (POLAR-RCT, n=511) showed no improvement in 6-month neurologic outcomes with early prophylactic hypothermia versus normothermia; does not support routine use.

    Cooper et al (2018).

    Occipital cryoneurolysis for cervicogenic headache: An RCT (n=52) showed substantial but temporary pain relief that was not significantly different from corticosteroid plus local anesthetic injections; consider only after positive diagnostic blocks and when noninvasive therapies are insufficient.

    Kvarstein et al (2019).

    Concussion management — investigational/limited evidence

    Selective head–neck cooling (concussion) evidence and regulatory status

    Head–neck cooling for sports-related concussion: Nonrandomized and small randomized pilot studies report shorter return-to-play times and faster symptom recovery with early selective head–neck cooling; studies are limited by small size, nonrandomized allocation, lack of blinding, and potential bias—evidence is preliminary.

    Gard et al (2021), Congeni et al (2022), Al-Husseini (2022).

    Device regulatory status: The pro2cool device had received FDA Breakthrough Device designation but was not FDA-cleared at the time of the document; use is considered investigational pending regulatory clearance and robust evidence.

    TecTraum/pro2cool status described in document.

    Cryoneurolysis for post-operative and cancer pain — preliminary evidence

    Percutaneous cryoneurolysis for post-operative and cancer pain

    Post-mastectomy cryoneurolysis: Small case series report very low pain scores and no opioid requirement post-operatively; authors recommend randomized trials to validate benefits.

    Gabriel et al (2020).

    Pectus excavatum (MIRPE) cryoanalgesia: Retrospective series (n=101) reported reduced inpatient opioid use and similar pain scores; concerns about thermal injury noted and larger prospective studies recommended.

    Parrado et al (2019).

    Splanchnic nerves cryoneurolysis for pancreatic cancer pain: Preliminary case series (n=5) reported marked pain score reduction and decreased analgesic use; randomized trials are needed to validate these findings.

    Filippiadis et al (2021).

    Trigeminal neuralgia — medically necessary criteria

    Selection criteria for cryoanalgesia in trigeminal neuralgia

    Trigeminal neuralgia selection: Members have experienced pain for at least 6 months AND have tried and failed pharmacotherapies (e.g., baclofen, carbamazepine, phenytoin) or are unable to tolerate medication side effects.6 months

    Repeat cryoanalgesia may be medically necessary every 6 months.

    The policy lists several specific indications and device categories as experimental/investigational and therefore not established for routine coverage. Examples include cryo neurolysis for abdominal pain related to pancreatic cancer, peripheral neuropathic pain, phantom limb pain, post-herpetic neuralgia, and intra‑operative or post‑operative cryoanalgesia for post‑thoracotomy or post‑tonsillectomy pain. Also designated investigational are devices that deliver both hot and cold therapy and passive cold compression units for indications other than those explicitly listed as medically necessary.

    Available studies do not demonstrate that complex active cold therapy systems with mechanical pumps or refrigeration confer additional clinical benefit compared with simpler passive devices such as the Cryo/Cuff or conventional ice packs. The document states there is no evidence that these more complicated cold therapy units provide any additional benefit over the CryoCuff or conventional ice bags or packs, and notes alignment with Medicare DME MAC policy regarding mechanical cold therapy pumps.

    The policy identifies several devices or device families that currently lack adequate evidence of safety and effectiveness or FDA marketing clearance for the listed indications. Examples called out include Kinex ThermoComp and VascuTherm2 (solid‑state continuous cold/compression systems) and other combinations of heating/cooling systems referenced in the scope (e.g., Aqua Relief System, ThermoPlus). Use of such devices for the described pain indications is considered investigational pending stronger evidence or regulatory authorization.

    Many of the clinical reports and series cited in the policy have methodological limitations that restrict generalizability. Common limitations include uncontrolled or unblinded designs, small sample sizes, single‑center or retrospective cohorts, and heterogeneity in patient selection and procedural technique. The policy therefore cautions that preliminary positive findings should be interpreted carefully and validated in randomized, adequately powered, and well‑controlled studies before broad adoption.

    This Clinical Policy Bulletin is developed to assist in the administration of plan benefits and is not an offer of coverage or medical advice. It provides a general summary of clinical evidence and coverage stance and does not constitute a contract; treating providers retain responsibility for clinical care decisions.

    The policy explicitly lists applications of therapeutic hypothermia and intra‑brain cooling that are not supported for routine use, including therapeutic induction of intra‑brain hypothermia (e.g., pro2cool), prophylactic hypothermia for traumatic brain injury, and therapeutic hypothermia for hemorrhagic stroke. These techniques are considered not established for the specified neurologic indications.

    Continuous cold therapy systems or Hot/Ice Machines have not been shown consistently to provide superior postoperative outcomes compared with standard cryotherapy (ice packs) or simpler passive units. The policy cites studies that failed to demonstrate consistent benefit and notes that routine use of continuous cold or Hot/Ice Machines for all post‑operative patients is not supported by the available data.

    Large randomized evidence does not support early prophylactic hypothermia for severe traumatic brain injury. The POLAR‑RCT (n=511) found no improvement in 6‑month neurologic outcomes with early prophylactic hypothermia compared with normothermia, and therefore early routine prophylactic hypothermia for severe TBI is not recommended.

    A double‑blind RCT of occipital cryoneurolysis for cervicogenic headache (n=52) demonstrated substantial but transient pain reductions that were not statistically different from corticosteroid plus local anesthetic injections. The authors concluded occipital cryoneurolysis may be considered only after positive diagnostic blocks and when less invasive therapies have been insufficient, and they raised concerns about potential local scar or neuroma formation with repeated procedures.

    CPT, HCPCS, and ICD-10 Codes

    Covered CPT CodesCPTCovered
    64600Destruction by neurolytic agent, trigeminal nerve; supraorbital, infraorbital, mental, or inferior alveolar branch.
    64620Destruction by neurolytic agent, intercostal nerve.
    CPT Codes Not Covered / RelatedCPT
    0440TAblation, percutaneous, cryoablation, includes imaging guidance; upper extremity distal/peripheral nerve.
    0441TAblation, percutaneous, cryoablation, includes imaging guidance; lower extremity distal/peripheral nerve.
    0442TAblation, percutaneous, cryoablation, includes imaging guidance; nerve plexus or other truncal nerve (eg, brachial plexus, pudendal nerve).
    0776TTherapeutic induction of intra-brain hypothermia, including placement of a mechanical temperature-controlled cooling device to the neck over carotids and head, including monitoring (eg, vital signs and sport concussion assessment tool 5 [SCAT5]), 30 minutes of treatment.
    64605Destruction by neurolytic agent, trigeminal nerve; second and third division branches at foramen ovale.
    64640Destruction by neurolytic agent; other peripheral nerve or branch.
    Other Related CPT CodesCPT
    19301-19307Mastectomy.
    21740-21743Reconstructive repair of pectus excavatum or carinatum.
    27447Arthroplasty, knee, condyle and plateau; medial AND lateral compartments with or without patella resurfacing.
    27486-27487Revision of total knee arthroplasty, with or without allograft; 1 component (27486) and femoral and entire tibial component (27487).
    64400Injection, anesthetic agent; trigeminal nerve, any division or branch.
    64420Intercostal nerve, single.
    64421Intercostal nerves, multiple, regional block.
    HCPCS Codes (DME and related)HCPCS
    A9273Hot water bottle, ice cap or collar, heat and/or cold wrap, any type.
    E0217Water circulating heat pad with pump.
    E0218Water circulating cold pad with pump.
    E0236Pump for water circulating pad.
    E0249Pad for water circulating heat unit.
    E0650Pneumatic compressor; non-segmental home.
    E0651Pneumatic compressor, segmental home model without calibrated gradient pressure.
    E0652Pneumatic compressor, segmental home model with calibrated gradient pressure.
    E0671Segmental gradient pressure pneumatic appliance; full leg.
    E0673Segmental gradient pressure pneumatic appliance, half leg.
    1–10 of 11
    1/2
    ICD-10 Codes Covered / Not Covered (examples)ICD-10
    G50.0Trigeminal neuralgia.
    G54.6Phantom limb syndrome with pain.
    M17.0-M17.9Osteoarthritis of knee.
    R52Pain, unspecified.
    Cryoprobe pressure and device specifics
    Cryoprobe operating pressureApproximately 600 pounds per square inch (high-pressure N2O or CO2 delivered through a 12–14 G cryoprobe)
    Needle/probe size12- to 14-gauge needle-shaped cryoprobe used to deliver cryogen
    Cryogen gasesTypically nitrous oxide or carbon dioxide are used as the high-pressure gas

    Authorization, Documentation, and Provider Requirements

    Prior Authorization

    Prior Authorization Alignment and Guidance

    Prior authorization may be required for certain devices or procedures referenced in this policy. Aetna’s approach to mechanical cold therapy pumps is aligned with Medicare DME MAC policy; prior authorization requirements and coverage determinations for these devices will follow that guidance. Prior authorization may also be required for home therapeutic cold devices or novel head–neck cooling systems that lack sufficient evidence or FDA clearance.

    • Prior authorization follows Medicare DME MAC policy for mechanical cold therapy pumps.
    • Active cold units with mechanical pumps and combined heat/cold devices may require prior authorization and are generally considered experimental/investigational for many indications.
    Prior Authorization

    Trigeminal Neuralgia: Selection Criteria and Repeat Interval

    For cryoanalgesia to treat trigeminal neuralgia, members must meet selection criteria: symptoms present for at least 6 months and a documented trial of, and failure of, appropriate pharmacotherapies (e.g., carbamazepine, baclofen, phenytoin) or documented intolerance to them. Repeat cryoanalgesia may be considered medically necessary no more often than every 6 months.

    • Pain duration ≥ 6 months.
    • Documented trial and failure of, or intolerance to, pharmacotherapies (e.g., carbamazepine, baclofen, phenytoin).
    • Repeat treatments: minimum 6-month interval between procedures.
    Denial Risk

    Evidence-Based Coverage Implication for Mechanical Cold Therapy Pumps

    Active cold therapy pumps and more complicated circulating units have not been shown to provide added clinical benefit over passive cold compression therapy. As a result, claims for active cold units with mechanical pumps or combined heat/cold systems may be considered experimental/investigational or not covered for many indications.

    • Mechanical circulating units with pumps lack evidence of superiority to passive hot/cold therapy.
    • Examples of active/complex systems: IceMan, Game Ready, AutoChill, BioCryo, VPULSE, Hilotherm.
    Denial Risk

    Evidence and Safety Risks

    Use of devices or procedures without adequate clinical evidence or demonstrated safety/effectiveness may be unsupported and subject to denial. Documented clinical rationale, relevant evidence, and justification for use of novel or less-established devices should be provided when seeking coverage.

    • Devices lacking peer-reviewed evidence of safety/effectiveness carry increased denial risk.
    • Provide clinical rationale and cite supportive literature when requesting coverage for novel devices.
    Denial Risk

    Regulatory Status Risk

    When a device is not cleared or authorized by the FDA for the requested indication, lack of regulatory clearance increases the risk that coverage will be denied. The pro2cool system (example) was not cleared by the FDA at the time of documentation and lacks market authorization, which should be noted in submissions.

    • If device is not FDA-cleared for the indication, include rationale and supporting evidence; coverage may be denied.
    • Example: pro2cool lacked FDA marketing authorization at the time of the referenced documentation.
    Note

    No Additional Explicit Prior Authorization or Denial Triggers

    There are no additional explicit prior authorization requirements or automatic denial triggers specified beyond those described above; determinations will be made based on the clinical indications, evidence, and existing coverage rules.

    • Absence of an explicit PA requirement in this section does not preclude case-by-case review.
    • Providers should verify member-specific benefits and PA rules.
    Documentation Required

    Clinical Documentation and Evidence

    Submit comprehensive clinical documentation to support the medical necessity of devices or procedures. Include the clinical rationale, prior conservative therapies tried, diagnostic test results, and citations to relevant peer-reviewed evidence when applicable.

    • Document clinical rationale and reference supporting evidence or literature.
    • Include prior conservative treatments and results of diagnostic/test blocks when applicable.
    Documentation Required

    Required Documentation

    Required documentation must be included with requests or claims: device model and manufacturer, indication for use, detailed treatment parameters (e.g., temperature, duration, compression settings), and FDA clearance status when applicable.

    • Device model and manufacturer.
    • Indication and clinical rationale.
    • Treatment parameters (temperature, duration, compression settings).
    • FDA clearance/authorization status if applicable.
    Documentation Required

    Required Clinical Documentation

    Include the following clinical details in chart notes and prior authorization submissions when relevant: indication (e.g., cervicogenic headache, occipital neuralgia, peripheral neuropathic pain, pre-op for TKA), results of diagnostic or prognostic test blocks, prior treatments and responses, and anticipated benefit.

    • Clearly state the indication (diagnosis code) and how selection criteria are met.
    • Provide results of diagnostic blocks or other objective assessments.
    • List prior therapies and response/tolerance.
    • Describe expected benefit and treatment plan.
    Note

    Policy References and Administrative Information

    This section of the policy contains references, policy history, and administrative information. Providers should consult the policy history and related policy links for updates and confirm the effective date and next review date when interpreting coverage.

    • Effective date: 1998-10-13; Next review date listed in policy header.
    • Review policy history and related CPBs for context and updates.
    Step Therapy

    Step Therapy Consideration

    Step therapy considerations: when evidence is limited for a procedure (e.g., occipital cryoneurolysis), consider requiring less invasive or more established diagnostic/therapeutic steps first (for example, diagnostic nerve blocks or conservative medical management) prior to approving cryoneurolysis.

    • Recommend diagnostic/test blocks and conservative therapies before approving cryoneurolysis for cervicogenic headache or occipital neuralgia.
    • Document responses to these prior steps in the medical record.

    Clinical Background and Definitions

    Active cold compression therapy units that incorporate mechanical pumps or refrigeration (for example, Game Ready, Breg Polar Care Cube, and similar systems) are listed as not covered for the indications described in the policy. The policy also lists devices that deliver both hot and cold therapy and other named systems in the scope as investigational or excluded from routine coverage for the listed pain and postoperative uses.

    Cryoanalgesia / Cryoablation — Key facts
    DefinitionCryoanalgesia/cryoablation is the delivery of very low temperatures via a probe (using gases such as nitrous oxide or carbon dioxide) to freeze peripheral nerves and produce temporary analgesia.
    Typical deliveryHigh-pressure gas administered through a needle-shaped cryoprobe to create focal freezing of nerve tissue
    Duration of effectProvides temporary pain relief; effects can be weeks to months depending on application
    Common indications notedUsed for refractory trigeminal neuralgia, intercostal nerve ablation during Nuss procedures, and various perioperative applications discussed in literature
    Active cold units — Definition and examples
    DefinitionActive cold units are mechanical cold therapy systems that use pumps or refrigeration to circulate cooled (or heated) fluid through a wrap, often providing cyclical compression via a pump-controlled system (examples: Game Ready, Breg Polar Care Cube, IceMan).
    ComponentsTypically consist of a wrap or pad plus a control unit or pump with a reservoir that circulates chilled water to the wrap
    Power sourceMay be battery- or electrically-operated pumps to automate water exchange and compression cycles
    Active cold therapy device — Definition/details
    DefinitionActive cold therapy device: a device that uses a mechanical or pneumatic pump to circulate cooled or heated fluid through a wrap and may combine intermittent pneumatic compression; examples include Game Ready, IceMan, Hilotherm.
    Intended functionProvide cyclical compression and controlled temperature therapy over treatment periods via automated circulation
    Typical clinical claimDesigned to maintain consistent cold distribution over large surface areas and remove need for manual water recycling
    Passive cold therapy device — Definition/details
    DefinitionPassive cold therapy device: a gravity- or hand pump–driven system without electrical power that circulates ice water through a cuff or wrap (examples: AirCast Cryo/Cuff, Polar Care Cub).
    MechanismIce water placed in a reservoir cooler elevated above the limb fills the cuff by gravity or via manual pump to provide cold and compression
    Clinical roleConsidered medically necessary DME for swelling, edema, hematoma, hemarthrosis, and pain when indicated; simpler than active systems
    Cryoanalgesia / Cryoablation — Peripheral nerve application
    DefinitionCryoanalgesia/cryoablation of peripheral nerves involves application of extreme cold via a probe to temporarily ablate nerve conduction (e.g., intercostal nerves during Nuss procedures) to reduce post-operative pain.
    Clinical effectAssociated in studies with decreased length of stay and reduced inpatient opioid consumption versus alternatives in Nuss procedures
    Technique notesThoracoscopic transthoracic and modified probe techniques described to access intercostal nerves during Nuss/MIRPE procedures
    Continuous cold/compression device — Definition/details
    DefinitionContinuous cold/compression device: solid-state, microprocessor-controlled systems that deliver cold without ice, intermittent compression, and optionally DVT prophylaxis (examples: Polar Care continuous systems, Kinex ThermoComp, VascuTherm2).
    FeaturesMicroprocessor-controlled temperatures, pre-programmed therapy cycles (contrast therapy), and automated compression cycles for home use
    Evidence noteDocument states lack of robust evidence for safety and effectiveness for some devices; routine superiority over passive therapy not established
    Selective head–neck cooling (pro2cool) — Definition/details
    DefinitionSelective head–neck cooling (pro2cool) is a portable device applied to the head and neck to cool blood in the carotid arteries and lower brain temperature, proposed for acute concussion management.
    Regulatory statusAt time of document the pro2cool system had Breakthrough Device designation but was not FDA-cleared for routine use; considered investigational until clearance and robust evidence are available.
    Treatment protocolDescribed as two 30-minute treatments with device-applied cooling over carotids and head, including monitoring (eg, vital signs, SCAT5).
    Cryoneurolysis/cryoneurolysis — Definition/details
    DefinitionCryoneurolysis (percutaneous) is application of freezing to peripheral nerves to produce a temporary conduction blockade for analgesia; techniques like Iovera provide extended-duration analgesia after a single application.
    Clinical findingsRCTs and series report substantial but temporary pain relief for some indications (eg, occipital cryoneurolysis), though differences versus steroid/local anesthetic injections may be non-significant.
    Risks and selectionMay be considered after positive diagnostic blocks; repeated procedures carry risks such as local scar or neuroma formation and potential neuropathic pain.
    Cryoneurolysis (Iovera) — Definition/details
    Iovera (cryoneurolysis technique)Percutaneous technique using exceptionally low temperatures to reversibly ablate a peripheral nerve, producing analgesia lasting weeks to months after a single application.
    Use contextDiscussed as an option for extended-duration regional analgesia; limited validation for acute pain and RCTs are needed to define benefits and risks.
    Comparison to PNSProduces sensory/motor changes (reversible nerve injury) whereas PNS provides analgesia without inducing sensory or motor deficits.
    Percutaneous peripheral nerve stimulation (PNS) — Definition and contrast
    DefinitionPercutaneous peripheral nerve stimulation (PNS) involves inserting an insulated lead adjacent to a peripheral nerve to deliver electrical current for analgesia without producing sensory or motor deficits.
    Duration and clearancePNS is cleared for up to 60 days of use in some applications; it does not ablate or injure the nerve like cryoneurolysis does.
    Contrast with cryo methodsUnlike cryoneurolysis/cryoablation, PNS provides analgesia via neuromodulation and preserves nerve integrity rather than producing reversible axonotmesis.
    Cold therapy units — Examples referenced
    Common examplesCold therapy units referenced across studies include Cryo/Cuff (AirCast), Polar Care (Breg), Game Ready, IceMan, Hilotherm, VPULSE, and continuous-flow cold therapy units.
    Passive examplesAirCast Cryo/Cuff System and Polar Care (PC) Cub Unit are frequently cited passive devices using gravity or hand pump circulation.
    Active examplesGame Ready Accelerated Recovery System, IceMan, Hilotherm, and VPULSE are noted active devices that combine pump-driven circulation with compression or heating functions.
    Cryoanalgesia / Cryoablation — Additional references
    Supplemental definitionCryoanalgesia/cryoablation uses extreme cold via a probe to freeze peripheral nerves for pain control in conditions such as trigeminal neuralgia and post-thoracotomy or intraoperative applications.
    MechanismFreezing induces reversible nerve injury that interrupts conduction and provides temporary analgesia with minimal permanent sensory loss reported in many series.
    Historical useDescribed in literature for decades for trigeminal neuralgia and other peripheral nerve pain conditions; selection criteria exist for TN applications.

    Prior Treatments and Diagnostic Requirements

    Failure or intolerance of medications required prior to cryoanalgesia.

    Failure or intolerance of medications required prior to cryoanalgesia.

    Medication failure or intolerance: Members must have tried and failed pharmacologic therapies (for example, carbamazepine, baclofen, phenytoin) or be unable to tolerate medication side effects prior to consideration of cryoanalgesia for trigeminal neuralgia.at least up to 6 months of pain duration and prior drug trial(s)

    See Appendix selection criteria; repeat procedures may be considered every 6 months.

    Treatment Frequency and Repeat Intervals

    General frequency guidance
    Frequency limits statementNo explicit frequency limits are listed in this section of the policy.
    Coding appendix implicationFrequency constraints may be specified in procedure-specific selection criteria (eg, TN repeat interval) rather than a general frequency table.
    Provider actionWhen planning repeat interventions, reference indication-specific guidance (eg, TN repeat every 6 months) in the Appendix.
    Intercostal nerve cryoablation — Frequency and notes
    Procedure referencedIntercostal nerve cryoablation (eg, during Nuss procedure) is described in technical and outcome literature, but no specific numeric frequency limit is provided in the policy section.
    Clinical outcomesStudies report reduced inpatient opioid use and decreased length of stay after intraoperative intercostal cryoablation.
    Imaging/technique noteThoracoscopic transthoracic techniques and probe modifications are described to access intercostal nerves during the Nuss procedure.
    Occipital cryoneurolysis — Frequency and clinical notes
    Frequency statementOccipital cryoneurolysis is discussed without specific procedural frequency limits described in the policy excerpts.
    Use conditionsPolicy and RCT findings suggest occipital cryoneurolysis may be considered only after positive diagnostic blocks and when noninvasive treatments are insufficient.
    Outcome noteRCT showed temporary pain relief not significantly different from steroid plus local anesthetic injections; repeated treatments raise concerns about neuroma or scarring.
    Cryoanalgesia for trigeminal neuralgia — Frequency and selection
    Trigeminal neuralgia repeat intervalRepeat cryoanalgesia may be medically necessary every 6 months for trigeminal neuralgia.
    Selection requirementMembers must have experienced pain for at least 6 months and have tried and failed pharmacotherapies (eg, baclofen, carbamazepine, phenytoin) or be unable to tolerate them prior to cryoanalgesia.
    Documentation implicationDocument prior medication trials and duration of symptoms when requesting repeat procedures within policy guidelines.
    Inventory placeholder — no data
    Inventory placeholderNo data available.

    Imaging and Procedural Guidance

    Documentation Required

    Imaging Guidance for Percutaneous Cryoablation Codes

    Imaging guidance is implied or required by CPT descriptions for percutaneous cryoablation codes (0440T–0442T); use imaging as documented in code descriptions when performing percutaneous cryoablation.

    • Ensure procedural documentation includes the imaging modality used consistent with code descriptors.
    Documentation Required

    Technical Notes — Intra-operative Cryoanalgesia for Nuss

    Intra-operative cryoanalgesia for the Nuss procedure uses thoracoscopic transthoracic or modified probe techniques; providers should follow the procedural methods described in the literature when performing these intra-operative techniques.

    • Techniques described include probe modification (insulation) to allow ipsilateral nerve ablation and approaches that avoid additional thoracoscopic ports.
    Documentation Required

    CT Guidance for Splanchnic Nerve Cryoneurolysis

    Percutaneous cryoneurolysis of the splanchnic nerves in reported series was performed under CT guidance; document imaging modality when claiming these procedures.

    • Report use of CT guidance and procedural details (posterolateral paravertebral approach, cryoprobe gauge).
    Documentation Required

    Ultrasound Guidance for Intercostal Cryoneurolysis

    Ultrasound guidance was used for percutaneous intercostal nerve cryoneurolysis in reported mastectomy case reports; document use of ultrasound if applicable.

    • Include US-guided localization technique and outcomes in procedural documentation.
    Documentation Required

    Imaging Guidance for Percutaneous Cryoneurolysis

    When percutaneous cryoneurolysis is performed in study protocols or for improved accuracy, use and document appropriate imaging guidance (ultrasound or CT) as reported in the literature.

    • Document imaging modality, localization technique (nerve stimulation/US), and procedural parameters in the record.
    Note

    Imaging Note — Intraoperative Intercostal Cryoablation

    References describing intraoperative intercostal cryoablation techniques for thoracic procedures do not specify imaging requirements in the cited excerpts; follow institution-specific standards and document the approach used.